Our results revealed a significant decrease in PD-1 expression on both CD4+ and CD8+ T lymphocytes in AML patients after effective treatment (p = 0.0040 and p = 0.0173, Fig. 4A, B). This evidence concerns the gene CD8A and acute myeloid leukemia.